Next evolution of CAR T-cell therapy is solid tumors
According to Sangamo CEO Sandy Macrae:
While chimeric antigen receptor (CAR) T-cell therapy has become a game-changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors.
We need to better understand which patients we should target against. I think the evolution of CAR T is understanding beyond the blood tumors into the solid tumors, and that I think is more challenging. However, if the industry is successful with creating allogeneic forms of the therapy "that could be given off-the-shelf" to patients urgently, then cancer could eventually become a "chronic disease of living.
Six CAR T-cell therapies have been approved by the U.S. Food and Drug Administration. All are approved for the treatment of blood cancers. When it comes to the use of CAR T cells to treat solid tumors, advances are hard to come by. However, research on CAR T cells is continuing a pace, including hundreds of ongoing clinical trials .
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=4276
ارسال به دوستان